Baylor Sammons Cancer Center Joins as Clinical Trial Site for Actinium’s Actimab-A Clinical Trial

  Baylor Sammons Cancer Center Joins as Clinical Trial Site for Actinium’s
  Actimab-A Clinical Trial

  Baylor Sammons Cancer Center Is One Of The Largest Oncology Centers In The
            Nation Treating Over 55,000 Cancer Patients Every Year

Business Wire

NEW YORK -- July 30, 2014

Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"),
a biopharmaceutical company developing innovative targeted payload
immunotherapeutics for the treatment of advanced cancers, today announced the
addition of  Baylor Charles A. Sammons Cancer Center as a clinical trial site
for Actimab-A. The center joins several other clinical trial sites currently
participating in the Actimab-A Phase I/II trial to potentially address the
rapid mortality and unmet medical need for older patients with newly diagnosed
acute myeloid leukemia (AML).

M. Yair Levy, MD, Medical Director of Hematologic Malignancy Clinical
Research, Baylor Research Institute, stated, “AML in the elderly is a disease
that is difficult to treat with few therapeutic options. Through our
participation, Baylor is pleased to be able to provide patients with the
ability to enroll in the Actimab-A Phase I/II clinical trial and gain access
to this innovative, targeted, low intensity therapy which is being evaluated
to address this deadly disease.”

Kaushik J. Dave, Ph.D., President and CEO of the Company stated, “We are
pleased to work with Baylor Charles A. Sammons Cancer Center, which is one of
the largest oncology centers in the nation treating over 55,000 cancer
patients every year. The selection reflects its commitment and significant
experience in conducting clinical trials to evaluate the newest strategies for
cancer prevention, diagnosis and treatment.”

The current Actimab-A clinical trial is titled “A Phase I/II Study of Low Dose
Cytarabine and Lintuzumab-Ac225 in Older Patients With Untreated Acute Myeloid
Leukemia” (ClinicalTrials.gov identifier NCT01756677). The Company expects to
provide interim results around the same time as the American Society of
Hematology (ASH) meeting in December 2014.

About Actimab-A

Actimab-A is a radiolabeled antibody being developed for newly diagnosed AML
in patients over 60, and is currently in a multicenter Phase I/II clinical
trial. Based on Actinium’s alpha-particle immunotherapy (APIT) platform,
Actimab-A consists of the CD33 antibody lintuzumab linked to the actinium-225
payload. Actimab-A has attracted support from leading experts at the
prestigious and high-volume cancer treatment hospitals due to the potential of
its safety and efficacy profile, as well as its potential potency, specificity
and ease of use. Clinical trials are being conducted at world-class cancer
institutions such as Memorial Sloan Kettering Cancer Center, Johns Hopkins
Medicine, University of Pennsylvania Health System, Fred Hutchinson Cancer
Research Center, MD Anderson Cancer Center and now the Texas Oncology-Baylor
Charles A. Sammons Cancer Center. The Company expects interim Phase I/II
clinical trial results in December 2014. Actimab candidates are in early
development for other cancers.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. (www.actiniumpharma.com) is a New York-based
biopharmaceutical company developing innovative targeted payload
immunotherapeutics for the treatment of advanced cancers. Actinium's targeted
radiotherapy is based on its proprietary delivery platform for the therapeutic
utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta
emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The
Company’s lead radiopharmaceutical Iomab™-B will be used in preparing patients
for hematopoietic stem cell transplant, commonly referred to as bone marrow
transplant. The Company is preparing a single, pivotal, multicenter Phase 3
clinical study of Iomab™-B in refractory and relapsed Acute Myeloid Leukemia
(AML) patients over the age of 55 with a primary endpoint of durable complete
remission. The Company’s second program, Actimab-A, is continuing its clinical
development in a Phase 1/2 trial for newly diagnosed AML patients over the age
of 60 in a single-arm multicenter trial.

Forward-Looking Statement for Actinium Pharmaceuticals, Inc.

This news release contains “forward-looking statements” as defined in the
Private Securities Litigation Reform Act of 1995. These statements are based
on management's current expectations and involve risks and uncertainties,
which may cause actual results to differ materially from those set forth in
the statements. The forward-looking statements may include statements
regarding product development, product potential, or financial performance. No
forward-looking statement can be guaranteed and actual results may differ
materially from those projected. Actinium Pharmaceuticals undertakes no
obligation to publicly update any forward-looking statement, whether as a
result of new information, future events, or otherwise.

Contact:

Actinium Pharmaceuticals, Inc.
Evan Smith, +1 646-840-5442
CFA, VP Investor Relations and Finance
esmith@actiniumpharma.com
 
Press spacebar to pause and continue. Press esc to stop.